Overview

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2020-12-28

Target enrollment:

Participant gender:

Summary

This is a Randomized, Double-blind, Multicenter Phase III Study Comparing Efficacy and Safety of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Bevacizumab Combined with Paclitaxel and Carboplatin for Treatment of Naïve Subjects with Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Phase:

Phase 3

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel